Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Want to see AU:PIQ full AI Analyst Report?
Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.26
▼(-60.75% Downside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by weak financial performance (steep revenue decline, ongoing losses, and negative operating/free cash flow). Technicals also remain unfavorable with the price below major moving averages and negative MACD. Low leverage provides limited support, but valuation is constrained by negative earnings and no dividend yield.
Positive Factors
Low leverage / balance sheet flexibility
A very low debt-to-equity ratio provides durable financial flexibility, reducing interest burden and refinancing risk. This supports continued R&D and commercialization efforts without heavy fixed financing costs, improving resilience over the next several months.
Negative Factors
Steep revenue decline
A pronounced revenue drop signals persistent demand or commercialisation issues, reducing operating scale and leverage. It undermines long-term gross profit conversion and makes it harder to fund growth internally without external capital over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet flexibility
A very low debt-to-equity ratio provides durable financial flexibility, reducing interest burden and refinancing risk. This supports continued R&D and commercialization efforts without heavy fixed financing costs, improving resilience over the next several months.
Read all positive factors
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$42.12M
Dividend YieldN/A
Average Volume (3M)426.90K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth7.65%
EPS Growth-19.13%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding165,184,000
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.43Price Target Upside-35.82% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$4.30M
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Company Description
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis a...
How the Company Makes Money
PIQ makes money primarily through two channels: (1) commercialisation of its diagnostic products and related testing services, and (2) fee-for-service laboratory/analytical work.
1) Diagnostics product and testing revenue: PIQ generates revenue f...
Proteomics International Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 480.45K | 960.39K | 892.14K | 730.34K | 1.49M | 1.31M |
| Gross Profit | -9.26M | 960.39K | -1.12M | -1.62M | -568.62K | 497.08K |
| EBITDA | -11.94M | -10.00M | -8.40M | -7.55M | -4.56M | -2.77M |
| Net Income | -9.66M | -8.11M | -6.38M | -6.23M | -4.97M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 11.30M | 14.78M | 10.88M | 10.08M | 5.40M | 8.60M |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 11.04M | 6.64M | 6.03M | 2.11M | 5.60M |
| Total Debt | 681.45K | 277.74K | 316.39K | 64.09K | 0.00 | 69.05K |
| Total Liabilities | 4.09M | 1.81M | 1.63M | 1.75M | 2.00M | 990.19K |
| Stockholders Equity | 7.45M | 13.17M | 9.41M | 8.38M | 3.39M | 7.61M |
Cash Flow | ||||||
| Free Cash Flow | -8.41M | -6.63M | -6.00M | -6.91M | -3.67M | -2.41M |
| Operating Cash Flow | -6.35M | -6.60M | -5.59M | -5.69M | -3.54M | -2.21M |
| Investing Cash Flow | -2.07M | -29.65K | -388.02K | -1.17M | -129.46K | -191.00K |
| Financing Cash Flow | 10.76M | 11.03M | 6.59M | 10.77M | 176.10K | 5.64M |
Proteomics International Laboratories Ltd. Technical Analysis
Negative
0.67
Price Trends
0.33
Negative
0.44
Negative
0.40
Negative
Market Momentum
-0.03
Negative
42.10
Neutral
42.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PIQ, the sentiment is Negative. The current price of 0.67 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.33, and above the 200-day MA of 0.40, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 42.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PIQ.
Proteomics International Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$74.43M | -0.82 | -93.08% | ― | 1114.27% | 85.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$6.63M | -0.15 | 2844.96% | ― | ― | 46.28% | |
42 Neutral | AU$54.68M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$63.09M | -4.29 | -254.33% | ― | ― | ― | |
41 Neutral | AU$42.12M | -4.45 | -93.66% | ― | 7.65% | -19.13% | |
41 Neutral | AU$150.38M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:PIQ
Proteomics International Laboratories Ltd.
0.28
-0.11
-29.49%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
13.33%
AU:NUZ
Pharmaust Limited
0.09
-0.03
-27.35%
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-9.09%
AU:RCE
Recce Pharmaceuticals Ltd.
0.57
0.28
96.55%
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Announces Departure of Director Neville Gardiner
Apr 17, 2026
Proteomics International Laboratories has announced that non-executive director Neville Gardiner has ceased to be a director of the company as of 16 April 2026. Gardiner holds no securities directly but retains indirect interests through the Gardi...
Proteomics International Restructures as It Accelerates Commercial Diagnostics Focus
Apr 16, 2026
Proteomics International Laboratories has undertaken an organisational restructure as it shifts from a predominantly research-driven operation to a commercially focused diagnostics company. The company specialises in proteomics-based precision dia...
Proteomics International Widens Half-Year Loss as Revenue Declines
Feb 24, 2026
Proteomics International Laboratories reported a weak first half for the six months to 31 December 2025, with operating and other activity revenues falling 30% to $357,000 and total income including grants and other revenue declining 10% to $868,7...
Proteomics International Founder Dr Richard Lipscombe Retires from Board
Feb 23, 2026
Proteomics International Laboratories Ltd announced the formal retirement of founder and Managing Director Dr Richard Lipscombe from its board of directors, effective 23 February 2026, after 25 years of leadership. His departure marks the end of a...
Proteomics International Seeks ASX Quotation for Additional 67,566 Shares
Feb 2, 2026
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 67,566 new fully paid ordinary shares under its code PIQ, with an issue date of 2 February 2026. The additional securities arise from the exercise or conversion of e...
Proteomics International Seeks ASX Quotation for 1.16m New Shares
Jan 21, 2026
Proteomics International Laboratories Ltd has applied to the ASX for quotation of 1,164,320 new ordinary fully paid shares, to be issued on 21 January 2026 under its ticker PIQ. The additional securities, arising from the exercise or conversion of...
Proteomics International Appoints David Morris to Board With No Initial Shareholding
Jan 19, 2026
Proteomics International Laboratories Ltd has appointed David Morris as a director effective 19 January 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Morris currently holds no relevant...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.